BICO Stock Overview
Operates as a bioconvergence company in North America, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BICO Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.62 |
| 52 Week High | SEK 72.30 |
| 52 Week Low | SEK 33.06 |
| Beta | 2.38 |
| 11 Month Change | -13.88% |
| 3 Month Change | -28.41% |
| 1 Year Change | -34.68% |
| 33 Year Change | -88.18% |
| 5 Year Change | -53.06% |
| Change since IPO | 154.09% |
Recent News & Updates
Recent updates
Here's Why BICO Group (STO:BICO) Can Afford Some Debt
Jul 01
The Market Doesn't Like What It Sees From BICO Group AB (publ)'s (STO:BICO) Earnings Yet As Shares Tumble 26%
Jun 08Why BICO Group AB (publ) (STO:BICO) Could Be Worth Watching
Dec 02Calculating The Fair Value Of BICO Group AB (publ) (STO:BICO)
May 20Is BICO Group AB (publ) (STO:BICO) Potentially Undervalued?
May 04Is BICO Group (STO:BICO) Using Too Much Debt?
Feb 09Health Check: How Prudently Does BICO Group (STO:BICO) Use Debt?
Oct 24Bullish: This Analyst Just Lifted Their Cellink AB (publ) (STO:CLNK B) Outlook For Next Year
Jul 22Shareholder Returns
| BICO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -7.5% | -5.3% | -2.1% |
| 1Y | -34.7% | 19.7% | 10.8% |
Return vs Industry: BICO underperformed the Swedish Life Sciences industry which returned 19.7% over the past year.
Return vs Market: BICO underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| BICO volatility | |
|---|---|
| BICO Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BICO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BICO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 832 | Maria Forss | www.bico.com |
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
BICO Group AB (publ) Fundamentals Summary
| BICO fundamental statistics | |
|---|---|
| Market cap | SEK 2.42b |
| Earnings (TTM) | -SEK 1.50b |
| Revenue (TTM) | SEK 2.42b |
1.0x
P/S Ratio-1.6x
P/E RatioIs BICO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BICO income statement (TTM) | |
|---|---|
| Revenue | SEK 2.42b |
| Cost of Revenue | SEK 684.50m |
| Gross Profit | SEK 1.74b |
| Other Expenses | SEK 3.24b |
| Earnings | -SEK 1.50b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -21.23 |
| Gross Margin | 71.75% |
| Net Profit Margin | -61.83% |
| Debt/Equity Ratio | 48.6% |
How did BICO perform over the long term?
See historical performance and comparison